|View printer-friendly version|
|February 13, 2005 9:59 a.m.|
|Teva Announces Tentative Approval Of Levofloxacin Injection|
Jerusalem, Israel, February 13, 2005 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's ANDAs for Levofloxacin Injection, 5 mg/mL in 250 mg/bag and 500 mg/bag (5% dextrose bags) and Levofloxacin Injection, 25 mg/mL in 20 mL and 30 mL vials. Final approval is subject to the resolution of ongoing patent litigation.